ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MLYS
CMPS (40) URGN (24) NBTX (49) RARE (23) ⌘ Pro Terminal →

Mineralys Therapeutics Inc. (MLYS) — RQD Stock Rating Cockpit

$18.18 -14.41% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.67

Mineralys Therapeutics Inc. (MLYS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.61B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MLYS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MLYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Mineralys Therapeutics Inc. (NASDAQ: MLYS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $18.18 (-14.41% 1D, market cap $1.61B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MLYS compare to CMPS and URGN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MLYS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.4%. By comparison, CMPS (COMPASS Pathways Plc American Depository Shares) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and URGN (UroGen Pharma Ltd.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B). Among the 5-stock peer group, MLYS leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MLYS?
▼

Per MLYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001933414), Mineralys Therapeutics Inc. generated $477.7M in revenue (-11.3% YoY), -$154.7M in net income, and -$142.4M in free cash flow against $661.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $17.67 (-2.78%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (5)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$50 Bull$16 Base$13 Bear
📬 FREE MLYS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MLYS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY MLYS SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$21.00+2.8% Next Q
Q2 (-2Q)
38
Grade E$21.58-2.1% Next Q
Q3 (-1Q)
36
Grade E$21.13-14% Next Q
Current
33
Grade E$18.18-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MLYS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MLYS currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.55) and Max Pain ($19.09) forces dealer call-delta covering toward $50.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MLYS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MLYS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
36.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $18$18.18H: $48
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MLYS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-28.4% ROIC with 42.0% gross margin and -7.58% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (25)

8/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like MLYS
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MLYS)

  • ✓Walkthrough of MLYS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MLYS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.68%🛡️ HOLDING TREND SUPPORT
2026-11-03O $21.24H $21.24L $18.18C $18.18VOL 3.98M
RES: $32.75SUP: $17.89SMA50: $24.55SMA200: $26.87
$34.16$29.81$25.46$21.11$16.76RES $32.75SUP $17.89$18.182026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MLYS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MLYS Butterfly Map → + Track MLYS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -11.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MLYS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MLYS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MLYS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MLYS)

Health Care Rank #668 of 1015 ⚔️ CMPS vs MLYS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MLYS vs. CMPS, URGN, NBTX, RARE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Mineralys Therapeutics Inc. (MLYS) ranks #668 by composite RQD confidence (33/100, grade E) and #289 by equity capitalization ($1.61B). Within this direct 5-issuer industry benchmark cohort, MLYS leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. NBTX currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with MLYS at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MLYS ACTIVE
Mineralys Therapeutics Inc.
E 33/100 — — -28.4% -14.41% $1.61B Benchmark Subject
CMPS
COMPASS Pathways Plc American Depository Shares
D- 40/100 — — -35.0% -5.09% $1.60B /cmps-vs-mlys →
URGN
UroGen Pharma Ltd.
E 24/100 — 88.7% -35.0% -2.27% $1.60B /urgn-vs-mlys →
NBTX
Nanobiotix S.A.
D 49/100 — — — -7.19% $1.59B /nbtx-vs-mlys →
RARE
Ultragenyx Pharmaceutical Inc.
E 23/100 — — -35.0% -4.05% $1.59B /rare-vs-mlys →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001933414 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mineralys Therapeutics Inc. (MLYS) reported GAAP revenue of $477.7M (-11.3% vs. FY2024 revenue of $538.7M , and +101.5% cumulative change since FY2023) , GAAP net income of -$154.7M, operating cash flow of -$142.4M, and free cash flow of -$142.4M (+14.4% YoY). On the balance sheet, MLYS closed FY2025 with $661.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $477.7M -$154.7M -$142.4M -$142.4M $661.8M —
FY2024 (FY) 2024-12-31 $538.7M -$177.8M -$166.3M -$166.3M $205.9M —
FY2023 (FY) 2023-12-31 $237.0M -$71.9M -$81.2M -$81.2M — —

3. MLYS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MLYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Mineralys Therapeutics Inc. (NASDAQ: MLYS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $18.18 (-14.41% 1D, market cap $1.61B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does MLYS compare to CMPS and URGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MLYS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.4%. By comparison, CMPS (COMPASS Pathways Plc American Depository Shares) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and URGN (UroGen Pharma Ltd.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B). Among the 5-stock peer group, MLYS leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MLYS?

Per MLYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001933414), Mineralys Therapeutics Inc. generated $477.7M in revenue (-11.3% YoY), -$154.7M in net income, and -$142.4M in free cash flow against $661.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MLYS trading relative to its 50-day, 200-day, and 52-week technical levels?

MLYS last traded at $18.18 (-14.41% on volume of 3,979,628 shares), positioning the stock -25.95% below its 50-day simple moving average ($24.55) and -32.34% below its 200-day simple moving average ($26.87). Across its 52-week range of $18.11 to $47.65, MLYS sits at the 0.2% percentile with a 14-day RSI of 36.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.91 to $20.45).

Direct Sub-Reports: MLYS RQD Cockpit MLYS 12M Forecast MLYS Earnings & Move MLYS Dividends & DRIP MLYS Insiders & 13F MLYS Whale Options MLYS Profit Sankey MLYS News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

MLYS — Mineralys Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Mineralys Therapeutics Inc. (MLYS) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $18.18 (-14.41% 1D, market capitalization $1.61B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -28.4%, gross margin of —, operating margin of —, and free cash flow yield of -7.58%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Mineralys Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations,. Reported revenue is — in each of the listed fiscal years, which indicates no revenue generation in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Mineralys Therapeutics Inc. (MLYS) reported $477.7M in annual revenue (up from $538.7M in FY2024, -11.3% YoY) and -$154.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($237.0M revenue, -$71.9M net income) through FY2025, MLYS scaled operating cash flow to -$142.4M and free cash flow to -$142.4M, backed by $661.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.58% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $18.11 – $47.65 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification. For a prospective investor, the key second-order question is whether the liquidity-beta exposure (2.93x) means MLYS would amplify broader liquidity shifts, though the weak correlation (r = -0.18) limits confidence in that relationship.

  • Key Question #1: Can MLYS sustain or expand its — operating margin and -28.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $477.7M and free cash flow of -$142.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MLYS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MLYS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mineralys Therapeutics Inc. (MLYS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MLYS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MLYS Bull vs. Bear Conversation Board — What's Your Call at $18.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MLYS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MLYS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $23.27 (+28.0%)
📌 Pinned Debate

Proprietary Butterfly liquidity signal rates MLYS a 91/100 Macro Tailwind Score with a 2.93x Net Liquidity beta, and FY 2025 cash rose

Picked up a starter position in MLYS in my $100K Virtual Cash book at $18.18. Proprietary Butterfly liquidity signal rates MLYS a 91/100 Macro Tailwind Score with a 2.93x Net Liquidity beta, and FY 2025 cash rose to $172.9M.. Trading inside a $18.11–$47.65 52-week range with -7.58% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@MeanReversion_88 Shorting a 5/20 institutional whale-flow stock at $18.18 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $14.36 (-21.0%)
Spot @ $18.18

The RQD rating scores MLYS 34/100 (grade E) with ROIC of -28.4%, FCF of -$142.4M in FY 2025, and insider-flow pillar at only 3/20.

Fading this rally in MLYS at $18.18. The RQD rating scores MLYS 34/100 (grade E) with ROIC of -28.4%, FCF of -$142.4M in FY 2025, and insider-flow pillar at only 3/20.. With a beta of 1.0 and the stock sitting at $18.18 (52-wk range $18.11–$47.65), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%